476 related articles for article (PubMed ID: 19482086)
41. Pathophysiology of tumor neovascularization.
Furuya M; Nishiyama M; Kasuya Y; Kimura S; Ishikura H
Vasc Health Risk Manag; 2005; 1(4):277-90. PubMed ID: 17315600
[TBL] [Abstract][Full Text] [Related]
42. The heterogeneity of cancer endothelium: The relevance of angiogenesis and endothelial progenitor cells in cancer microenvironment.
Armani G; Pozzi E; Pagani A; Porta C; Rizzo M; Cicognini D; Rovati B; Moccia F; Pedrazzoli P; Ferraris E
Microvasc Res; 2021 Nov; 138():104189. PubMed ID: 34062191
[TBL] [Abstract][Full Text] [Related]
43. Evolutionary emergence of angiogenesis in avascular tumors using a spatial public goods game.
Salimi Sartakhti J; Manshaei MH; Basanta D; Sadeghi M
PLoS One; 2017; 12(4):e0175063. PubMed ID: 28399181
[TBL] [Abstract][Full Text] [Related]
44. Why haven't we cured cancer?
Harding E
Lancet Oncol; 2017 Jul; 18(7):861-862. PubMed ID: 28677566
[No Abstract] [Full Text] [Related]
45. Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies.
Shojaei F; Ferrara N
Drug Resist Updat; 2008 Dec; 11(6):219-30. PubMed ID: 18948057
[TBL] [Abstract][Full Text] [Related]
46. Orai1 and transient receptor potential channels as novel molecular targets to impair tumor neovascularization in renal cell carcinoma and other malignancies.
Moccia F; Dragoni S; Poletto V; Rosti V; Tanzi F; Ganini C; Porta C
Anticancer Agents Med Chem; 2014 Feb; 14(2):296-312. PubMed ID: 23869775
[TBL] [Abstract][Full Text] [Related]
47. Bone marrow-derived proangiogenic cells in pancreatic cancer.
Mizukami Y
J Gastroenterol Hepatol; 2012 Mar; 27 Suppl 2():23-6. PubMed ID: 22320912
[TBL] [Abstract][Full Text] [Related]
48. Evading tumor evasion: current concepts and perspectives of anti-angiogenic cancer therapy.
Abdollahi A; Folkman J
Drug Resist Updat; 2010; 13(1-2):16-28. PubMed ID: 20061178
[TBL] [Abstract][Full Text] [Related]
49. Role of Angiogenesis and Its Biomarkers in Development of Targeted Tumor Therapies.
Pathak A; Pal AK; Roy S; Nandave M; Jain K
Stem Cells Int; 2024; 2024():9077926. PubMed ID: 38213742
[TBL] [Abstract][Full Text] [Related]
50. Cancer immunotherapy of targeting angiogenesis.
Hou J; Tian L; Wei Y
Cell Mol Immunol; 2004 Jun; 1(3):161-6. PubMed ID: 16219162
[TBL] [Abstract][Full Text] [Related]
51. Inhibitors of Angiogenesis.
Büning H; Hacker UT
Adv Exp Med Biol; 2016; 917():261-85. PubMed ID: 27236560
[TBL] [Abstract][Full Text] [Related]
52. Consensus micro RNAs governing the switch of dormant tumors to the fast-growing angiogenic phenotype.
Almog N; Ma L; Schwager C; Brinkmann BG; Beheshti A; Vajkoczy P; Folkman J; Hlatky L; Abdollahi A
PLoS One; 2012; 7(8):e44001. PubMed ID: 22952847
[TBL] [Abstract][Full Text] [Related]
53. The Discovery of Tumor Angiogenesis Factors: A Historical Overview.
Ribatti D
Methods Mol Biol; 2016; 1464():1-12. PubMed ID: 27858351
[TBL] [Abstract][Full Text] [Related]
54. Histone deacetylases: anti-angiogenic targets in cancer therapy.
Mottet D; Castronovo V
Curr Cancer Drug Targets; 2010 Dec; 10(8):898-913. PubMed ID: 20718701
[TBL] [Abstract][Full Text] [Related]
55. Anti-angiogenesis and angioprevention: mechanisms, problems and perspectives.
Bisacchi D; Benelli R; Vanzetto C; Ferrari N; Tosetti F; Albini A
Cancer Detect Prev; 2003; 27(3):229-38. PubMed ID: 12787731
[TBL] [Abstract][Full Text] [Related]
56. Novel anti-angiogenic therapies for malignant gliomas.
Norden AD; Drappatz J; Wen PY
Lancet Neurol; 2008 Dec; 7(12):1152-60. PubMed ID: 19007739
[TBL] [Abstract][Full Text] [Related]
57. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation.
Bögler O; Mikkelsen T
Cancer J; 2003; 9(3):205-13. PubMed ID: 12952305
[TBL] [Abstract][Full Text] [Related]
58. Tumor angiogenesis and anti-angiogenic therapies.
Shahneh FZ; Baradaran B; Zamani F; Aghebati-Maleki L
Hum Antibodies; 2013; 22(1-2):15-9. PubMed ID: 24284305
[TBL] [Abstract][Full Text] [Related]
59. [Angiogenesis and antiangiogenic cancer therapy].
Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
[TBL] [Abstract][Full Text] [Related]
60. The angiogenic process as a therapeutic target in cancer.
Bridges EM; Harris AL
Biochem Pharmacol; 2011 May; 81(10):1183-91. PubMed ID: 21382350
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
